Close Menu

NEW YORK (GenomeWeb) – Grail has raised $900 million out of a planned $1 billion, in the first close a Series B financing round that was led by Arch Venture Partners and included Johnson and Johnson Innovation as well as Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck, Tencent Holdings, and Varian Medical Systems. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.